Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)
NCT02132754
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
116
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
BIOLOGICAL:
MK-4166
BIOLOGICAL:
Pembrolizumab
Sponsor
Merck Sharp & Dohme LLC